| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
|
Yamamoto, Noboru
|
|
2018
|
82 |
4 |
p. 685-694
|
article
|
| 2 |
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
|
Greil, Richard
|
|
2018
|
82 |
4 |
p. 695-706
|
article
|
| 3 |
A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)
|
Tanaka, Yusuke
|
|
2018
|
82 |
4 |
p. 585-592
|
article
|
| 4 |
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors
|
Liu, Stephen V.
|
|
2018
|
82 |
4 |
p. 723-732
|
article
|
| 5 |
Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients
|
Akiyama, Kana
|
|
2018
|
82 |
4 |
p. 717-721
|
article
|
| 6 |
Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer
|
Yamazaki, Haruhiko
|
|
2018
|
82 |
4 |
p. 649-654
|
article
|
| 7 |
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1
|
Jain, Mukul R.
|
|
2018
|
82 |
4 |
p. 635-647
|
article
|
| 8 |
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
|
Moehler, Markus
|
|
2018
|
82 |
4 |
p. 733-739
|
article
|
| 9 |
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients
|
Saito, Kosuke
|
|
2018
|
82 |
4 |
p. 677-684
|
article
|
| 10 |
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy
|
Shibuya, Hitoshi
|
|
2018
|
82 |
4 |
p. 661-668
|
article
|
| 11 |
Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
|
Zhang, Wen
|
|
2018
|
82 |
4 |
p. 655-660
|
article
|
| 12 |
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models
|
Martin, Emma C.
|
|
2018
|
82 |
4 |
p. 669-675
|
article
|
| 13 |
Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer
|
Nishimura, Junichi
|
|
2018
|
82 |
4 |
p. 707-716
|
article
|
| 14 |
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer
|
Huang, Weiwei
|
|
2018
|
82 |
4 |
p. 607-613
|
article
|
| 15 |
Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation
|
Ni, Feng
|
|
2018
|
82 |
4 |
p. 593-605
|
article
|
| 16 |
Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
|
Li, Jing
|
|
2018
|
82 |
4 |
p. 571-583
|
article
|
| 17 |
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer
|
Yamaguchi, Kyoko
|
|
2018
|
82 |
4 |
p. 625-633
|
article
|
| 18 |
Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects
|
Zhang, Hong
|
|
2018
|
82 |
4 |
p. 615-623
|
article
|
Journal description